SZShaolong Zhu

Shaolong Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shaolong Zhu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • HDX-MS epitope characterization for evaluating antibody suitability for ELISA-based in vitro potency testing of vaccines

    by Alex Listigovers, Liwei He, Lidice Bernardo Reyes, Camille Houy, Luciano Ettorre, Nelson Eng, Jason Szeto, Romain Pizzato, Derek J. Wilson, D. Andrew James, et al.

    ELISA requirements: a crosslinked toxoid presents immune epitopes. Antibodies are screened by hydrogen deuterium exchange. Antibodies targeting separated neutralizing epitopes support in vitro potency testing, replacing in vivo .

  • Epitope screening using Hydrogen/Deuterium Exchange Mass Spectrometry (HDX‐MS): An accelerated workflow for evaluation of lead monoclonal antibodies

    by Shaolong Zhu, Peter Liuni, Tricia Chen, Camille Houy, Derek J. Wilson, D. Andrew James

    Background: Epitope mapping is an increasingly important aspect of biotherapeutic and vaccine development. Recent advances in therapeutic antibody design and production have enabled candidate mAbs to be identified at a rapidly increasing rate, resulting in a significant bottleneck in the characterization of “structural” epitopes, that are challenging to determine using existing high throughput epitope mapping tools. Here, a Hydrogen/Deuterium Exchange Mass Spectrometry (HDX‐MS) epitope screening workflow was introduced that is well suited for accelerated characterization of epitopes with a common antigen.Main methods and major results: The method is demonstrated on set of six candidate mAbs targeting Pertactin (PRN). Using this approach, five of the six epitopes were unambiguously determined using two HDX mixing timepoints in 24 h total run time, which is equivalent to the instrument time required to map a single epitope using the conventional workflow.Conclusion: An accelerated HDX‐MS epitope screening workflow was developed. The “screening” workflow successfully characterized five (out of six attempted) novel epitopes on the PRN antigen; information that can be used to support vaccine antigenicity assays.


  • Open Access

    Epitope Screening Using Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS): An Optimized Workflow for Accelerated Evaluation of Lead Monoclonal Antibodies

    by Shaolong Zhu, Peter Liuni, Tricia Chen, Camille Houy, Derek Wilson, Andrew James

    Background: Epitope mapping is an increasingly important aspect of biotherapeutic and vaccine development. Recent advances in therapeutic antibody design and production has enabled candidate mAbs to be identified at a rapidly increasing rate resulting in a significant bottleneck in the characterization of ‘structural’ epitopes, that are challenging to determine using existing high throughput epitope mapping tools. Here, Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS) epitope screening workflow was introduced that is well suited for accelerated characterization of epitopes with a common antigen. Main methods and major results: The method is demonstrated on set of 6 candidate mAbs targeting Pertactin (PRN). Using this approach, five of the six epitopes was unambiguously determined using two HDX mixing timepoints in 24 hours total run time, corresponding to substantial decrease in the instrument time required to map a single epitope using conventional HDX workflows. Conclusion: An accelerated HDX-MS epitope screening workflow was developed. The two-timepoint ‘screening’ workflow mapped all six mAbs and generated high confidence epitopes for five of the six mAbs assayed. The substantial improvement in the rate of data collection can advance HDX-MS for higher throughput investigations supporting the ability to evaluate a broader number of mAb candidates at an earlier stage of vaccine development.

  • Hydrogen–Deuterium Exchange Epitope Mapping Reveals Distinct Neutralizing Mechanisms for Two Monoclonal Antibodies against Diphtheria Toxin

    by Shaolong Zhu, Peter Liuni, Luciano Ettorre, Tricia Chen, Jason Szeto, Bruce Carpick, D. Andrew James, Derek J. Wilson

    The Diphtheria toxoid (DT) antigen is one of the major components in pediatric and booster combination vaccines and is known to raise a protective humoral immune response upon vaccination. However, a structurally resolved analysis of Diphtheria toxin (DTx) epitopes with underlying molecular mechanisms of antibody neutralization has not yet been reported. Using hydrogen deuterium exchange mass spectrometry (HDX-MS) and Bio-Layer Interferometry (BLI) assays, we have characterized two neutralizing anti-DTx monoclonal antibodies (mAbs), 2-25 and 2-18, by identifying the specific epitopes on Diphtheria toxin responsible for antibody binding. Our results show that both epitopes are conformational, and mechanistically distinct. mAb 2-25 binds selectively to the B-subunit (translocation and receptor domain) of DTx, blocking the Heparin-binding EGF-like growth factor (HBEGF) binding site. In contrast, mAb 2-18 binds to the A-subunit (catalytic domain), partially covering the catalytic loop region that shuttles NAD during catalysis. The results are discussed in the context of antigen neutralization mechanisms and can ultimately help to reveal the underlying factors that contribute to Diptheria vaccine efficacy.